Table 2.
Clinical characteristics of acute-onset vitreous hemorrhage (VH) of preoperatively unknown origin.
| All | RVO | wAMD | Retinal break | Other | p | |
|---|---|---|---|---|---|---|
| Number of eyes | 169 | 77 | 21 | 50 | 24 | 0.001 |
| Age (y) | 63.64 ± 12.37 | 65.36 ± 9.82 | 73.29 ± 8.30 | 58.50 ± 11.78 | 60.63 ± 17.14 | <0.001∗ |
| Sex (male/female) | 83/86 | 33/41 | 11/10 | 31/19 | 8/16 | 0.216† |
| Right/left | 88/81 | 38/36 | 9/12 | 29/21 | 12/12 | 0.093† |
| Follow-up duration (mo.) | 13.24 ± 14.52 | 11.34 ± 11.59 | 15.62 ± 19.19 | 15.56 ± 17.00 | 12.21 ± 12.49 | 0.360∗ |
| Gauge of surgery | 0.098† | |||||
| 20-gauge | 19/169 (11.2%) | 10/74 (13.5%) | 5/21 (23.8%) | 3/50 (6.0%) | 1/24 (4.2%) | |
| 23/25-gauge | 150/169 (88.8%) | 64/74 (86.5%) | 16/21 (76.2%) | 47/50 (94.0%) | 23/24 (95.8%) | |
| Tamponade | <0.001† | |||||
| No tamponade | 56/169 (33.1%) | 34/74 (45.9%) | 4/21 (19.0%) | 9/50 (18.0%) | 9/24 (37.5%) | |
| Air | 55/169 (32.5%) | 32/74 (43.2%) | 1/21 (4.8%) | 13/50 (26.0%) | 9/24 (37.5%) | |
| C3F8 | 24/169 (14.2%) | 3/74 (4.1%) | 1/21 (4.8%) | 19/50 (38.0%) | 1/24 (4.2%) | |
| Silicone oil | 34/169 (20.1%) | 5/74 (6.8%) | 15/21 (71.4%) | 9/50 (18.0%) | 5/24 (20.8%) | |
| Systemic disease | ||||||
| Hypertension | 92/169 (54.4%) | 48/74 (64.9%) | 13/21 (61.9%) | 17/50 (34.0%) | 14/24 (54.4%) | 0.006† |
| Duration (y) | 8.44 ± 7.85 | 8.55 ± 8.46 | 6.92 ± 5.39 | 6.90 ± 5.52 | 11.57 ± 9.76 | 0.329∗ |
| Diabetes | 20/169 (11.8%) | 9/74 (12.2%) | 2/21 (9.5%) | 7/50 (14/0%) | 2/24 (8.3%) | 0.891† |
| Duration (y) | 9.56 ± 8.46 | 7.56 ± 4.95 | 6.50 ± 4.95 | 12.71 ± 4.45 | 13.44 ± 9.50 | 0.658∗ |
| Anticoagulant | 51/169 (30.2%) | 34/74 (45.9%) | 3/21 (14.3%) | 8/50 (16.0%) | 6/24 (25.0%) | 0.001† |
RVO, retinal vein occlusion; wAMD, wet age-related macular degeneration.
∗According to one-way ANOVA with the Bonferroni post test.
†According to the Chi-square test.